Experimental mRNA CAR-T therapy targets autoimmune diseases in early trial
Disease control
Recruiting now
This early-phase study tests a new treatment called Arnovie101 for people with lupus or autoimmune hemolytic anemia. The therapy uses mRNA to create CAR-T cells inside the body, aiming to target and control overactive immune cells. Only 5 participants will be enrolled to check sa…
Phase: EARLY_PHASE1 • Sponsor: Circunited BioPharma (Shenzhen) Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC